Research progress on PD-1/PD-L1 inhibitors in the treatment of non-small cell lung cancer
- VernacularTitle:PD-1/PD-L1 抗体治疗晚期非小细胞肺癌研究进展
- Author:
Wenliang BAI
1
;
Lei LIU
1
;
Guige WANG
1
;
Jiaqi ZHANG
1
;
Shanqing LI
1
Author Information
1. Department of Thoracic Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100730, P.R.China
- Publication Type:Journal Article
- Keywords:
Non-small cell lung cancer;
anti-tumor immune effect;
programmed cell death-1/programmed cell death-ligand 1 (PD-1/PD-L1);
review
- From:
Chinese Journal of Clinical Thoracic and Cardiovascular Surgery
2020;27(08):953-959
- CountryChina
- Language:Chinese
-
Abstract:
Programmed cell death-1 (PD-1)/programmed cell death-ligand 1 (PD-L1) signaling pathway has been found capable of affecting anti-tumor immune effect in many malignancies in recent years. Patients who are diagnosed with advanced non-small cell lung cancer (NSCLC) have considerable responses after receving inhibitors against PD-1/PD-L1. This paper reviews the clinical progress of PD-1/PD-L1 inhibitors in the treatment of NSCLC.
